Australia Proposes Pharmacist-Only Supply For Low-Strength Hydroquinone

Australia’s Therapeutic Goods Administration has published an interim decision proposing pharmacist-only supply for hydroquinone preparations containing 2% or less for external therapeutic or cosmetic treatment of hyperpigmentation. The notice is dated 5 November 2026; the proposed scheduling changes are not final.

The delegate proposes replacing the current Schedule 2 pharmacy-medicine entry with a Schedule 3 pharmacist-only entry. The scope excludes monobenzone and alkyl ethers of hydroquinone included in Schedule 4.

Change From The Original Proposal

The original application sought deletion of Schedule 2 so that the affected products would fall under the prescription-only Schedule 4 framework. The interim decision instead supports Schedule 3 supply.

The delegate says pharmacist oversight and advice may reduce inappropriate use of low-strength hydroquinone for broad skin lightening while maintaining access. Higher-concentration human therapeutic or cosmetic preparations would remain within the prescription-only framework.

Exceptions And Advertising

Hair preparations containing 0.3% or less hydroquinone and cosmetic nail preparations containing 0.02% or less would remain exempt from scheduling. These exceptions are preserved in the proposed entries.

The decision also supports an Appendix H entry, allowing advertising of the Schedule 3 medicine, and consequential changes to Schedules 4 and 6. It states that the existing Appendix E and F labelling requirements are maintained.

Consultation And Proposed Start Date

The TGA consultation notice invites comments by 4 December 2026. Submissions will inform the final decision.

For hydroquinone, the delegate proposes implementation on 1 February 2028, allowing time for compliance and Product Information and Consumer Medicine Information documentation. That date remains proposed rather than an operative deadline.